How Should We Conduct and Interpret Phase III Clinical Trials in Palliative Care?

References 

1. Wildiers H, Dhaenekint C, Demeulenaere P, et al. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage. 2009;38(1):124–133
   • Abstract
   • Full Text
   • Full-Text PDF (348 KB)
   • CrossRef
2. Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;(1):CD005177
3. Agar M, Currow D, Plummer J, et al. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med. 2009;23(3):257–265
   • CrossRef
4. Clark K, Lam L, Currow D. Reducing gastric secretions—a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction?. Support Care Cancer. 2009 Mar 17;[Epub ahead of print]
5. Dentith JR, Hardy JR. Approval by MREC of a modified patient information and consent form. Does this set a precedent for trials in palliative care?. Palliat Med. 2004;18(5):484–485
   • MEDLINE
6. Rees E, Hardy J. Novel consent process for research in dying patients unable to give consent. BMJ. 2003;327(7408):198
   • CrossRef
7. Masso M, Dodds S, Fildes D, Yeatman H, Eagar K. Ethical research in palliative care: A guide through the Human Research Ethics Committee process. Wollongong, Australia: Centre for Health Service Development, University of Wollongong; 2004;